Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway

[Display omitted] Inbonemetabolism,osteoclastsare the only cellscapableofresorbingbone. Hyperactivity of osteoclasts may lead to osteolytic disease like osteoporosis and arthritis. Although there are several drugs for the treatment of osteolytic diseases, they have limitations and a variety of side...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochemical pharmacology 2023-09, Vol.215, p.115704-115704, Article 115704
Hauptverfasser:	Mao, Yi, Xie, Xinru, Jiang, Ting, Chao, Rui, Wan, Tianhao, Sun, Lei, Sun, Guangxin, Zhou, Zihang, Xu, Weifeng, Chen, Xuzhuo, Zhang, Shanyong
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone resorption JAK inhibitor MAPK signaling pathway Osteoclast XL019
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!